Pharma: Clinic roundup
Wednesday, April 30, 2014
Upsher-Smith Laboratories Inc., of Maple Grove, Minn., reported phase I data for USL261 (investigational intranasal midazolam) in patients with epilepsy were presented at the 66th Annual American Academy of Neurology (AAN) meeting in Philadelphia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.